HSBC Holdings’s Theriva Biologics TOVX Stock Holding History

HSBC Holdings’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-2	Closed	-$13K	–	2575
2016 Q4	$13K	Buy	+2	New	+$20.5K	﹤0.01%	2710

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HSBC Holdings's TOVX Position: Q1 2017 in Review

HSBC Holdings sold out of Theriva Biologics (TOVX) in Q1 2017, closing a stake of 2 shares — an estimated $13K sold.

HSBC Holdings first reported a position in TOVX in Q4 2016 and held it in 1 quarter. The position peaked at $13K in Q4 2016. 74 funds tracked by Wall St. Rank hold TOVX as of Q1 2017.

HSBC Holdings reported no remaining Theriva Biologics position as of Q1 2017 after selling out during the quarter.
HSBC Holdings sold 2 Theriva Biologics shares in Q1 2017, an estimated $13K.
HSBC Holdings first reported a position in Theriva Biologics in Q4 2016 and held it in 1 quarter.
HSBC Holdings's Theriva Biologics position peaked at $13K in Q4 2016.
74 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2017.

Based on HSBC Holdings's 13F filing for Q1 2017, filed 15 May 2017.